Aim Immunotech Inc (AIM)

$0.96 +0.04 (4.46%)
Market Cap 3.14M
Revenue (ttm) 170,000.00
Net Income (ttm) -17.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,188.24%
Debt to Equity Ratio 0.00
Volume 1,714,200
Avg Vol 5,486,212
Day's Range N/A - N/A
Shares Out 3.28M
Stochastic %K 31%
Beta 1.26
Analysts Sell
Price Target $14.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
AlertsAndNews
AlertsAndNews Mar. 21 at 8:44 PM
Highlights from last week. Some big runs on $SWMR $AIM $SER $ANNA $TLYS - Link in bio for more. All trading and investing involves a risk of loss. Do your own due diligence always!
0 · Reply
cardinals420
cardinals420 Mar. 21 at 1:45 AM
$AIM shorts through the weekend surprising . Something brewing. Shorts might be in trouble
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Mar. 20 at 7:55 PM
$AIM 👏🏼 lfg TUWOY earnings Monday
0 · Reply
SpacemanLoot
SpacemanLoot Mar. 20 at 7:22 PM
🚨 Mid-Day momentum gainers🚨 $ARBB micro float starting a squeeze up 🚀🚀 $AIM 1$ compliance 🔥 $PLUG Call buys looks will pay here 💎 $SMCI Oversold bounce trade 📈
0 · Reply
Revenge4my401k
Revenge4my401k Mar. 20 at 6:56 PM
$AIM 33 days out
0 · Reply
mkinvestinggroup
mkinvestinggroup Mar. 20 at 6:05 PM
$AIM
0 · Reply
mkinvestinggroup
mkinvestinggroup Mar. 20 at 5:56 PM
$AIM where are tens of millions of shares you short scumbags 🤮you deserved to be gama squeezed out
0 · Reply
MRVivke
MRVivke Mar. 20 at 5:44 PM
$AIM nothing doing anywhere. Bad market, folks on the sidelines, not even interested in a catalyst curing cancer. Need volume, until then easy hold.
0 · Reply
Kyle123
Kyle123 Mar. 20 at 5:43 PM
$AIM c-mon shorts, if you’re going to preset crosses at least hid it better. The SEC is absolutely corrupt
0 · Reply
M2023
M2023 Mar. 20 at 5:17 PM
$AIM I might sell for 50$ this is gold mine
1 · Reply
Latest News on AIM
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

Mar 18, 2026, 8:36 AM EDT - 3 days ago

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

AIM ImmunoTech Announces Closing of its Rights Offering

Mar 6, 2026, 7:00 PM EST - 15 days ago

AIM ImmunoTech Announces Closing of its Rights Offering

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

Mar 2, 2026, 9:00 AM EST - 19 days ago

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

Feb 27, 2026, 9:00 AM EST - 22 days ago

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

Feb 23, 2026, 8:55 AM EST - 26 days ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

Feb 12, 2026, 4:35 PM EST - 5 weeks ago

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 8:30 AM EST - 5 weeks ago

AIM ImmunoTech Announces Commencement of Rights Offering

Aimia Inc. (AIM:CA) M&A Call Transcript

Feb 9, 2026, 12:14 PM EST - 5 weeks ago

Aimia Inc. (AIM:CA) M&A Call Transcript

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 6, 2026, 8:55 AM EST - 6 weeks ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Feb 5, 2026, 8:40 AM EST - 6 weeks ago

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

Jan 23, 2026, 1:22 PM EST - 2 months ago

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Dec 1, 2025, 8:55 AM EST - 3 months ago

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Nov 18, 2025, 8:55 AM EST - 4 months ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 4 months ago

Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 10, 2025, 8:55 AM EST - 4 months ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Nov 4, 2025, 9:05 AM EST - 4 months ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 5 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 25, 2025, 8:45 AM EDT - 6 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Sep 4, 2025, 11:00 AM EDT - 7 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 7 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 9:00 AM EDT - 7 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 8:55 AM EDT - 7 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 6, 2025, 9:00 AM EDT - 8 months ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Aug 4, 2025, 9:00 AM EDT - 8 months ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 28, 2025, 11:12 AM EDT - 8 months ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jul 2, 2025, 8:55 AM EDT - 9 months ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 20, 2025, 4:15 PM EDT - 9 months ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 9 months ago

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:30 AM EDT - 10 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 12, 2025, 8:00 AM EDT - 10 months ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 10 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:54 AM EDT - 11 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

May 8, 2025, 8:45 AM EDT - 11 months ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 7, 2025, 1:26 PM EDT - 1 year ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:45 PM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 4, 2025, 4:05 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 9:19 AM EDT - 1 year ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 1 year ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 28, 2025, 8:45 AM EST - 1 year ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 1:20 PM EST - 1 year ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 26, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 25, 2025, 8:30 AM EST - 1 year ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:45 AM EST - 1 year ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 11, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Feb 7, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 23, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 22, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Jan 15, 2025, 9:05 AM EST - 1 year ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 4:45 PM EST - 1 year ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

AlertsAndNews
AlertsAndNews Mar. 21 at 8:44 PM
Highlights from last week. Some big runs on $SWMR $AIM $SER $ANNA $TLYS - Link in bio for more. All trading and investing involves a risk of loss. Do your own due diligence always!
0 · Reply
cardinals420
cardinals420 Mar. 21 at 1:45 AM
$AIM shorts through the weekend surprising . Something brewing. Shorts might be in trouble
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Mar. 20 at 7:55 PM
$AIM 👏🏼 lfg TUWOY earnings Monday
0 · Reply
SpacemanLoot
SpacemanLoot Mar. 20 at 7:22 PM
🚨 Mid-Day momentum gainers🚨 $ARBB micro float starting a squeeze up 🚀🚀 $AIM 1$ compliance 🔥 $PLUG Call buys looks will pay here 💎 $SMCI Oversold bounce trade 📈
0 · Reply
Revenge4my401k
Revenge4my401k Mar. 20 at 6:56 PM
$AIM 33 days out
0 · Reply
mkinvestinggroup
mkinvestinggroup Mar. 20 at 6:05 PM
$AIM
0 · Reply
mkinvestinggroup
mkinvestinggroup Mar. 20 at 5:56 PM
$AIM where are tens of millions of shares you short scumbags 🤮you deserved to be gama squeezed out
0 · Reply
MRVivke
MRVivke Mar. 20 at 5:44 PM
$AIM nothing doing anywhere. Bad market, folks on the sidelines, not even interested in a catalyst curing cancer. Need volume, until then easy hold.
0 · Reply
Kyle123
Kyle123 Mar. 20 at 5:43 PM
$AIM c-mon shorts, if you’re going to preset crosses at least hid it better. The SEC is absolutely corrupt
0 · Reply
M2023
M2023 Mar. 20 at 5:17 PM
$AIM I might sell for 50$ this is gold mine
1 · Reply
hitab
hitab Mar. 20 at 4:55 PM
$AIM broke 1.00😃😃
0 · Reply
Snorken
Snorken Mar. 20 at 4:52 PM
$AIM Wake me when Bristol Meyers give us $100!
1 · Reply
BottomzUp
BottomzUp Mar. 20 at 4:51 PM
$AIM has some movement.
0 · Reply
Mountain_Skis
Mountain_Skis Mar. 20 at 4:47 PM
$AIM 👀
0 · Reply
hitab
hitab Mar. 20 at 4:42 PM
$AIM @ 99..........
0 · Reply
hitab
hitab Mar. 20 at 4:38 PM
$AIM heading to breake 1.00 and then flyyyyyyyyyyyyy
0 · Reply
DandyDane
DandyDane Mar. 20 at 4:37 PM
$AIM picking up momentum
0 · Reply
hitab
hitab Mar. 20 at 4:35 PM
$AIM up to 135k
0 · Reply
cardinals420
cardinals420 Mar. 20 at 4:35 PM
$AIM
0 · Reply
hitab
hitab Mar. 20 at 4:33 PM
$AIM 47k shares bought in less then a minute
0 · Reply
hitab
hitab Mar. 20 at 4:33 PM
$AIM its flamin up😃
0 · Reply
PapiReese
PapiReese Mar. 20 at 3:55 PM
$AIM
0 · Reply